T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This study tests EB103, a new T-cell therapy (a type of treatment that uses engineered immune cells to fight cancer), in adults with B-cell non-Hodgkin's lymphoma that has relapsed or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older with confirmed B-cell non-Hodgkin's lymphoma - Your cancer has relapsed or failed to respond after at least 2 lines of treatment (or 1 line for Burkitt, mantle cell, or precursor B-cell lymphoma) - You previously received an anti-CD20 antibody (like rituximab) and anthracycline-based chemotherapy - Your disease is PET-scan positive - Your organ function is adequate **You may NOT be eligible if...** - You have active brain involvement from lymphoma - You have active serious infections or uncontrolled autoimmune disease - You are pregnant or breastfeeding - Your organ function is too impaired to safely receive the therapy Talk to your doctor to see if this trial is right for you.